Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children

Status Completed

Clinical Trial Summary

To evaluate the safety profile of amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 90/3.2 mg/kg/day (formulation 1) or at 80/2.85 mg/kg/day (formulation 2) in two divided doses for 10 days. Investigators will focus on the proportion of subjects who develop protocol-defined diarrhea and proportion who develop diaper dermatitis that occasions the prescription of antifungal medication.

Clinical Trial Description

Amoxicillin-clavulanate potassium has been shown to be efficacious in eradicating causative pathogens in acute otitis media (AOM) with resulting high clinical cure rates at end-of-treatment (85%). However, relatively high rates (~25%) of clinically significant diarrhea have been reported, the occurrence of which has been directly related to the clavulanate potassium component of the drug combination. A reduced concentration of clavulanate potassium in the drug formulation would be expected to have an improved safety profile regarding the occurrence of diarrhea. This study will examine whether the concentration of the clavulanate potassium component of amoxicillin-clavulanate potassium could be reduced in the treatment of children 6 months through 23 months of age diagnosed with AOM using stringent criteria. A total of 75 participants (n=75) with AOM will receive amoxicillin-clavulanate potassium (600 mg/21.5 mg/5 mL; 28:1) administered at 90/3.2 mg/kg/day (formulation 1) or at 80/2.85 mg/kg/day (formulation 2) in two divided doses for 10 days.

The primary outcome measure will be rates of clinically significant diarrhea and diaper dermatitis. These rates will be compared with the rate observed in our previous studies of AOM in children who received amoxicillin-clavulanate potassium (600 mg/42.9 mg/5 mL; 14:1) administered at 90/6.4 mg/kg/day in two divided doses for 10 days.

A subset of this group will have pharmacokinetic studies performed. Each participant that agrees will have a single blood draw (n=50). Investigators will analyze amoxicillin and clavulanate potassium in the blood samples using validated methods. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02630992
Study type	Interventional
Source	University of Pittsburgh
Contact
Status	Completed
Phase	Phase 3
Start date	December 2015
Completion date	July 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02092454` - Study to Assess the Safety and Efficacy of Benzocaine for Pain Relief in Children Presenting With Acute Otitis Media	Phase 2
Completed	`NCT01202578` - Evaluation of the Tympanostomy Tube Delivery System	Phase 2/Phase 3
Withdrawn	`NCT00502450` - Is There Hearing Loss After Acute Mastoiditis	N/A
Completed	`NCT04296448` - Evaluation of Cellphone Based Otoscopy in Pediatric Patients	N/A
Terminated	`NCT05651633` - Analgesic Ear Drops for Children With Acute Otitis Media	Phase 3
Completed	`NCT01941381` - Does Tympanometry Predict Antibiotic Usage in Acute Otitis Media?
Completed	`NCT02345447` - Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence	Phase 3
Recruiting	`NCT01214538` - Assessment of the Natural Antibody Response to Pneumococcal Surface Proteins During Acute Otitis Media in Children	N/A
Completed	`NCT03614117` - Effect of a New Probiotic Strain on Recurrent Acute Otitis Media in Children (PROMAR)	N/A
Recruiting	`NCT06027593` - Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions	N/A
Completed	`NCT02918773` - Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto)	N/A
Completed	`NCT02567747` - Vaccination Impact Against Pneumococcal Disease on Acute Otitis Media Morbidity in Colombian Children < 5 Years of Age
Completed	`NCT02935374` - Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children	Phase 4
Completed	`NCT02567825` - Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media	N/A
Completed	`NCT02037893` - Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media	Phase 2
Completed	`NCT00578773` - A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea	Phase 2
Completed	`NCT00377260` - Acute Otitis Media (AOM) Therapy Trial in Young Children	Phase 4
Completed	`NCT00645112` - A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media	Phase 4
Completed	`NCT00368823` - A Trial of Point of Care Information in Ambulatory Pediatrics	Phase 3
Completed	`NCT01272999` - Impact of Prevnar 13 on Ear Infections in Children

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms